Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.51 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CBFB | Q13951 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.43 |
| ▸ | TUBB | P07437 | 1/20 | 0.43 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22912723 | 1.00 | PARP1 (0.51) | PARP1PARP2KCNH2EGFRSMN1; SMN2 | |
| SCHEMBL22912787 | 0.89 | KDM4E (0.59) | PARP1PARP2EGFRSMN1; SMN2NPC1 | |
| SCHEMBL29396632 | 0.89 | KDM4E (0.59) | PARP1PARP2EGFRSMN1; SMN2NPC1 | |
| SCHEMBL22912681 | 0.86 | EGFR (0.48) | PARP1PARP2KCNH2EGFRSMN1; SMN2 | |
| SCHEMBL29394277 | 0.86 | EGFR (0.48) | PARP1PARP2KCNH2EGFRSMN1; SMN2 | |
| SCHEMBL22912799 | 0.86 | PARP1 (0.51) | PARP1PARP2KCNH2EGFRSMN1; SMN2 | |
| SCHEMBL29396728 | 0.86 | PARP1 (0.51) | PARP1PARP2KCNH2EGFRSMN1; SMN2 | |
| SCHEMBL15745613 | 0.80 | CBFB (0.48) | PARP1PARP2ALDH1A1HSD17B10CBFB | |
| SCHEMBL22912784 | 0.80 | PARP1 (0.52) | PARP1PARP2KCNH2EGFRSMN1; SMN2 | |
| SCHEMBL22912828 | 0.80 | PARP1 (0.52) | PARP1PARP2KCNH2EGFRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116348115-B | Combination of antibody-drug conjugate and PARP1 selective inhibitor | ASTRAZENECA UK LTD. (GB) | 2026-05-26 | — | — | CN | disclosed |
| US-12606555-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2026-04-21 | — | — | US | disclosed |
| CN-114144413-B | PARP1 inhibitors | 阿斯利康(瑞典)有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20230372527-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2023-11-23 | — | — | US | disclosed |
| CN-116348115-A | Combination of antibody-drug conjugate and PARP1 selective inhibitor | 阿斯利康(英国)有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20220227768-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2022-07-21 | — | — | US | disclosed |
| EP-3999506-A1 | PARP1 INHIBITORS | Astrazeneca AB (SE) | 2022-05-25 | — | — | EP | disclosed |
| CN-114144413-A | PARP1 inhibitors | 阿斯利康(瑞典)有限公司 | 2022-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606555-B2 | Chemical compounds | PARP1, PARP11, PARP12 | PARP1 1/4885PARP2 5/4885KCNH2 1441/4885 |
| US-20220227768-A1 | CHEMICAL COMPOUNDS | CYP11B2, CYP11B1, CYP4B1 | PARP1 399/4885PARP2 586/4885KCNH2 926/4885 |
| US-20230372527-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | PARP12, PARP11, PARP1 | PARP1 3/4885PARP2 8/4885KCNH2 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.